Oncocyte Corporation/$IMDX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Oncocyte Corporation
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Ticker
$IMDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
48
ISIN
US68235C2061
Website
IMDX Metrics
BasicAdvanced
$82M
-
-$3.34
0.96
-
Price and volume
Market cap
$82M
Beta
0.96
52-week high
$4.75
52-week low
$2.51
Average daily volume
112K
Financial strength
Current ratio
3.745
Quick ratio
3.57
Long term debt to equity
20.298
Total debt to equity
34.038
Interest coverage (TTM)
-237.73%
Profitability
EBITDA (TTM)
-21.578
Gross margin (TTM)
54.46%
Net profit margin (TTM)
-1,514.57%
Operating margin (TTM)
-606.25%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-22.17%
Return on equity (TTM)
-428.96%
Valuation
Price to revenue (TTM)
12.925
Price to book
7.98
Price to tangible book (TTM)
-18.6
Price to free cash flow (TTM)
-2.11
Free cash flow yield (TTM)
-47.39%
Free cash flow per share (TTM)
-135.07%
Growth
Revenue change (TTM)
178.08%
Earnings per share change (TTM)
-31.29%
3-year revenue growth (CAGR)
38.26%
3-year earnings per share growth (CAGR)
-39.99%
10-year earnings per share growth (CAGR)
-5.11%
IMDX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oncocyte Corporation stock?
Oncocyte Corporation (IMDX) has a market cap of $82M as of July 07, 2025.
What is the P/E ratio for Oncocyte Corporation stock?
The price to earnings (P/E) ratio for Oncocyte Corporation (IMDX) stock is 0 as of July 07, 2025.
Does Oncocyte Corporation stock pay dividends?
No, Oncocyte Corporation (IMDX) stock does not pay dividends to its shareholders as of July 07, 2025.
When is the next Oncocyte Corporation dividend payment date?
Oncocyte Corporation (IMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Oncocyte Corporation?
Oncocyte Corporation (IMDX) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.